sibn-20200331
falseMarch 31, 20202020Q1SI-BONE, Inc.0001459839December 31Accelerated FilertruetruefalseP6M00014598392020-01-012020-03-31xbrli:shares00014598392020-04-30iso4217:USD00014598392020-03-3100014598392019-12-31iso4217:USDxbrli:shares00014598392019-01-012019-03-310001459839us-gaap:CommonStockMember2019-12-310001459839us-gaap:AdditionalPaidInCapitalMember2019-12-310001459839us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001459839us-gaap:RetainedEarningsMember2019-12-310001459839us-gaap:CommonStockMember2020-01-012020-03-310001459839us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001459839us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001459839us-gaap:RetainedEarningsMember2020-01-012020-03-310001459839us-gaap:CommonStockMember2020-03-310001459839us-gaap:AdditionalPaidInCapitalMember2020-03-310001459839us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001459839us-gaap:RetainedEarningsMember2020-03-310001459839us-gaap:CommonStockMember2018-12-310001459839us-gaap:AdditionalPaidInCapitalMember2018-12-310001459839us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001459839us-gaap:RetainedEarningsMember2018-12-3100014598392018-12-310001459839us-gaap:CommonStockMember2019-01-012019-03-310001459839us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310001459839us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310001459839us-gaap:RetainedEarningsMember2019-01-012019-03-310001459839us-gaap:CommonStockMember2019-03-310001459839us-gaap:AdditionalPaidInCapitalMember2019-03-310001459839us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310001459839us-gaap:RetainedEarningsMember2019-03-3100014598392019-03-310001459839us-gaap:IPOMember2018-10-012018-10-310001459839us-gaap:IPOMember2018-10-310001459839sibn:FollowOnPublicOfferingMember2020-01-012020-01-310001459839sibn:FollowOnPublicOfferingAndSecondaryOfferingMember2020-01-012020-01-310001459839sibn:FollowOnPublicOfferingMember2020-01-310001459839us-gaap:OverAllotmentOptionMember2020-02-012020-02-290001459839us-gaap:OverAllotmentOptionMember2020-02-290001459839sibn:FollowOnPublicOfferingMember2020-01-012020-03-310001459839sibn:SecondaryOfferingMember2020-01-012020-03-31sibn:segment0001459839country:US2020-01-012020-03-310001459839country:US2019-01-012019-03-310001459839us-gaap:NonUsMember2020-01-012020-03-310001459839us-gaap:NonUsMember2019-01-012019-03-310001459839us-gaap:MoneyMarketFundsMember2020-03-310001459839us-gaap:USTreasurySecuritiesMember2020-03-310001459839us-gaap:CorporateDebtSecuritiesMember2020-03-310001459839us-gaap:CommercialPaperMember2020-03-310001459839us-gaap:MoneyMarketFundsMember2019-12-310001459839us-gaap:CommercialPaperMember2019-12-310001459839us-gaap:USTreasurySecuritiesMember2019-12-310001459839us-gaap:CorporateDebtSecuritiesMember2019-12-310001459839us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-03-310001459839us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-03-310001459839us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-03-310001459839us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-03-310001459839us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:FairValueMeasurementsRecurringMember2020-03-310001459839us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2019-12-310001459839us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2019-12-310001459839us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2019-12-310001459839us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2019-12-310001459839us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:FairValueMeasurementsRecurringMember2019-12-310001459839us-gaap:MachineryAndEquipmentMember2020-03-310001459839us-gaap:MachineryAndEquipmentMember2019-12-310001459839us-gaap:ConstructionInProgressMember2020-03-310001459839us-gaap:ConstructionInProgressMember2019-12-310001459839sibn:ComputerAndOfficeEquipmentMember2020-03-310001459839sibn:ComputerAndOfficeEquipmentMember2019-12-310001459839us-gaap:LeaseholdImprovementsMember2020-03-310001459839us-gaap:LeaseholdImprovementsMember2019-12-310001459839us-gaap:FurnitureAndFixturesMember2020-03-310001459839us-gaap:FurnitureAndFixturesMember2019-12-310001459839sibn:EricBFromerChiropracticIncClassActionMembersibn:LitigationStatutoryDamagesPerViolationOfTCPAMember2019-02-062019-02-060001459839sibn:EricBFromerChiropracticIncClassActionMembersibn:LitigationTrebleDamagesPerViolationOfTCPAMember2019-02-062019-02-060001459839us-gaap:IndemnificationGuaranteeMember2020-01-012020-03-310001459839us-gaap:IndemnificationGuaranteeMember2020-03-310001459839us-gaap:SecuredDebtMembersibn:PharmakonTermLoanMember2017-10-012017-10-31xbrli:pure0001459839us-gaap:SecuredDebtMembersibn:PharmakonTermLoanMember2017-10-310001459839sibn:PrepaymentPenalty3148MonthsMemberus-gaap:SecuredDebtMembersibn:PharmakonTermLoanMember2017-10-310001459839us-gaap:SecuredDebtMembersibn:PharmakonTermLoanMembersibn:PrepaymentPenalty4960MonthsMember2017-10-310001459839us-gaap:SecuredDebtMembersibn:PharmakonTermLoanMember2020-01-012020-03-310001459839us-gaap:SecuredDebtMembersibn:PharmakonTermLoanMember2019-01-012019-03-310001459839us-gaap:EmployeeStockOptionMember2020-01-012020-03-310001459839us-gaap:EmployeeStockOptionMembersrt:MinimumMember2020-01-012020-03-310001459839srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-03-310001459839us-gaap:EmployeeStockOptionMembersrt:MinimumMember2019-01-012019-03-310001459839srt:MaximumMemberus-gaap:EmployeeStockOptionMember2019-01-012019-03-310001459839us-gaap:EmployeeStockOptionMember2019-01-012019-03-310001459839us-gaap:RestrictedStockUnitsRSUMember2019-12-310001459839us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-310001459839us-gaap:RestrictedStockUnitsRSUMember2020-03-310001459839sibn:A2018EmployeeStockPurchasePlanMember2020-01-012020-03-310001459839sibn:A2018EmployeeStockPurchasePlanMember2020-03-310001459839sibn:A2018EmployeeStockPurchasePlanMember2019-12-310001459839sibn:A2018AmendedEmployeeStockPurchasePlanMember2020-03-262020-03-26sibn:purchase_period0001459839us-gaap:CostOfSalesMember2020-01-012020-03-310001459839us-gaap:CostOfSalesMember2019-01-012019-03-310001459839us-gaap:SellingAndMarketingExpenseMember2020-01-012020-03-310001459839us-gaap:SellingAndMarketingExpenseMember2019-01-012019-03-310001459839us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-03-310001459839us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-03-310001459839us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-03-310001459839us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-03-310001459839us-gaap:EmployeeStockOptionMember2020-01-012020-03-310001459839us-gaap:EmployeeStockOptionMember2019-01-012019-03-310001459839us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-310001459839us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-03-310001459839sibn:ShareSubjectToRepurchaseMember2020-01-012020-03-310001459839sibn:ShareSubjectToRepurchaseMember2019-01-012019-03-310001459839sibn:EmployeeStockPurchasePlanSharesMember2020-01-012020-03-310001459839sibn:EmployeeStockPurchasePlanSharesMember2019-01-012019-03-310001459839sibn:CommonStockWarrantsMember2020-01-012020-03-310001459839sibn:CommonStockWarrantsMember2019-01-012019-03-310001459839sibn:DevelopmentAgreementMembersrt:AffiliatedEntityMember2020-01-012020-03-310001459839sibn:DevelopmentAgreementMembersrt:AffiliatedEntityMember2020-03-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q


(Mark one)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________

Commission File Number: 001-38701

SI-BONE, INC.
(Exact Name of Registrant as Specified in its Charter)
 

Delaware
26-2216351
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification Number)

471 El Camino Real, Suite 101, Santa Clara, California95050
(Address of principal executive offices)(Zip Code)
 Registrant's telephone number, including area code: (408) 207-0700
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per shareSIBNThe Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.  
Large accelerated filer  o
Accelerated filer  x
Non-accelerated filer  o
Smaller reporting company  x
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   No x
The number of shares outstanding of the registrant’s Common Stock was 28,427,133 as of April 30, 2020.



TABLE OF CONTENTS

    Page
PART I-FINANCIAL INFORMATION 
 
PART II-OTHER INFORMATION










1


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, prospective products and product candidates, sales force expansion, surgeon adoption, reimbursement determinations, clinical trial results, and U.S. Food and Drug Administration ("FDA") approvals, are forward-looking statements.

These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions, including those described under the sections in this Quarterly Report entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These forward-looking statements include, but are not limited to, statements about the following:

impact the COVID-19 pandemic will have on our company, including our operations, financial results and liquidity and capital resources, the existence and duration of state and local orders temporarily prohibiting elective procedures including procedures using the iFuse Implant System, the ability and desire of patients and physicians to undergo and perform such procedures, the duration of the COVID-19 pandemic, and whether the COVID-19 pandemic will recur in the future;
our ability to maintain a healthy workforce in light of the ongoing COVID-19 pandemic;
our expectation that a significant portion of our revenues will be derived from sales of the iFuse Implant System, or iFuse;
our ability to develop additional revenue opportunities, including new indications for use and new devices;
our ability to retain and grow our sales team based on the demand for our products;
our ability to identify, train, and retain surgeons to perform procedures using our products;
our ability to obtain and maintain favorable coverage and reimbursement determinations from third-party payors;
our estimates of our market opportunity;
our expectations regarding the scope of protection from intellectual property rights covering our products;
developments or disputes concerning our intellectual property or other proprietary rights;
timing of and results from clinical and other trials;
marketing clearances and authorization from the FDA and regulators in other jurisdictions;
timing of regulatory filings and feedback;
competition in the markets we serve;
our expectations of the reliability and performance of our product;
our expectations of the benefits to patients, providers, and payors of our products;
our reliance on a limited number of suppliers, including sole source suppliers, which may impact the availability of instruments and materials;
our ability to sustain or increase demand for our products;
our estimates regarding our costs and risks associated with our international operations and expansion;
our expectations regarding our ability to retain and recruit key personnel;
our expectations regarding acquisitions and strategic operations;
2


our ability to fund our working capital requirements;
our compliance with, and the cost of, federal, state, and foreign regulatory requirements;
the factors that may impact our financial results; and
anticipated trends and challenges in our business and the markets in which we operate.

Forward-looking statements are based on management’s current expectations, estimates, forecasts, and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this report may turn out to be inaccurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this report. These statements, like all statements in this report, speak only as of their date. We caution investors that our business and financial performance are subject to substantial risks and uncertainties. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future, except as may be required by law.


3



PART I-FINANCIAL INFORMATION

Item 1. Financial Statements


SI-BONE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)

March 31, 2020December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents$67,568  $10,435  
Short-term investments77,373  81,345  
Accounts receivable, net of allowance for doubtful accounts of $272 and $238, respectively
9,361  11,720  
Inventory5,726  5,452  
Prepaid expenses and other current assets1,936  2,510  
Total current assets161,964  111,462  
Long-term investments1,274  1,278  
Property and equipment, net4,269  3,954  
Other non-current assets312  315  
TOTAL ASSETS $167,819  $117,009  
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$2,577  $2,811  
Accrued liabilities and other9,284  11,605  
Current portion of long-term borrowings8,731  4,358  
Total current liabilities20,592  18,774  
Long-term borrowings30,557  34,865  
Other long-term liabilities400  362  
TOTAL LIABILITIES51,549  54,001  
Commitments and contingencies (Note 6)
STOCKHOLDERS’ EQUITY
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding
    
Common stock, $0.0001 par value; 100,000,000 shares authorized; 28,406,128 and 25,163,803 shares issued and outstanding, respectively
3  3  
Additional paid-in capital
323,922  258,121  
Accumulated other comprehensive income
697  464  
Accumulated deficit
(208,352) (195,580) 
TOTAL STOCKHOLDERS’ EQUITY116,270  63,008  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$167,819  $117,009  

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4



SI-BONE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
(Unaudited)

Three Months Ended
March 31,
20202019
Revenue
$16,821  $14,991  
Cost of goods sold
1,932  1,526  
Gross profit14,889  13,465  
Operating expenses:
Sales and marketing19,281  15,815  
Research and development2,090  1,683  
General and administrative5,400  4,766  
Total operating expenses
26,771  22,264  
Loss from operations
(11,882) (8,799) 
Interest and other income (expense), net:
Interest income498  744  
Interest expense(1,231) (1,230) 
Other expense, net(157) (60) 
Net loss
$(12,772) $(9,345) 
Other comprehensive income (loss):
Changes in foreign currency translation
12  (19) 
Unrealized gain on marketable securities
221  25  
Comprehensive loss
$(12,539) $(9,339) 
Net loss per share, basic and diluted
$(0.47) $(0.38) 
Weighted-average number of common shares used to compute basic and diluted net loss per share
27,252,409  24,390,648  

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5


SI-BONE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(In thousands, except share amounts)
(Unaudited)
Common Stock
Additional
Paid-in
Capital
Accumulated
Other
Comprehensive
Income
Accumulated
Deficit
Total
Stockholders’ Equity
SharesAmount
Balance as of December 31, 201925,163,803  $3  $258,121  $464  $(195,580) $63,008  
Issuance of common stock from public offering, net of underwriting discounts, commissions and offering costs3,135,053  —  62,978  —  —  62,978  
Issuance of common stock upon exercise of stock options, net of shares withheld43,334  —  174  —  —  174  
Issuance of common stock upon vesting of restricted stock units63,938  —  —  —  —    
Stock-based compensation—  —  2,622  —  —  2,622  
Vesting of early exercised stock options—  —  27  —  —  27  
Foreign currency translation—  —  —  12  —  12  
Unrealized gain on marketable securities—  —  —  221  —  221  
Net loss—  —  —  —  (12,772) (12,772) 
Balance as of March 31, 202028,406,128  $3  $323,922  $697  $(208,352) $116,270  

Common Stock
Additional
Paid-in
Capital
Accumulated
Other
Comprehensive
Income
Accumulated
Deficit
Total
Stockholders’ Equity
SharesAmount
Balance as of December 31, 201824,450,757  $3  $246,927  $439  $(157,177) $90,192  
Issuance of common stock upon exercise of stock options, net of shares withheld46,809  —  125  —  —  125  
Stock-based compensation—  —  1,871  —  —  1,871  
Vesting of early exercised stock options—  —  66  —  —  66  
Additional accrual of IPO related costs—  —  (160) —  —  (160) 
Foreign currency translation—  —  —  (19) —  (19) 
Unrealized gain on marketable securities—  —  —  25  —  25  
Net loss—  —  —  —  (9,345) (9,345) 
Balance as of March 31, 201924,497,566  $3  $248,829  $445  $(166,522) $82,755  

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6



 
SI-BONE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Three Months Ended
March 31,
20202019
Cash flows from operating activities
Net loss
$(12,772) $(9,345) 
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation2,622  1,871  
Depreciation and amortization249  193  
Bad debts expense192    
Accretion on marketable securities(25) (479) 
Amortization of debt issuance costs65  65  
Loss on sale and disposal of property and equipment  97  
Changes in operating assets and liabilities:
Accounts receivable2,207  87  
Inventory(256) (165) 
Prepaid expenses and other assets581  (167) 
Accounts payable76  451  
Accrued liabilities and other(2,294) 314  
Net cash used in operating activities(9,355) (7,078) 
Cash flows from investing activities
Maturities of marketable securities21,000  17,600  
Purchases of marketable securities(16,777) (22,741) 
Purchases of property and equipment(884) (412) 
Net cash provided by (used in) investing activities3,339  (5,553) 
Cash flows from financing activities
Proceeds from follow-on public offering, net of underwriting discounts, commissions and offering costs62,978    
Proceeds from the exercise of stock options 174  125  
Net cash provided by financing activities63,152  125  
Effect of exchange rate changes on cash and cash equivalents
(3) (53) 
Net decrease in cash and cash equivalents57,133  (12,559) 
Cash and cash equivalents at
Beginning of period
10,435  25,120  
End of period
$67,568  $12,561  
Supplemental disclosure of non-cash information
Vesting of early exercised stock options
$27  $66  
Purchases of property and equipment included in accounts payable and accrued liabilities
$52  $140  
Public offering costs included in accounts payable
$  $167  
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7


SI-BONE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)


1. The Company and Nature of Business
SI-BONE, Inc. (the “Company”) was incorporated in the state of Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its primary product, the iFuse Implant System, or iFuse, in 2009 in the U.S., in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.
In October 2018, the Company completed its initial public offering ("IPO"), by issuing 8,280,000 shares of common stock, at an offering price of $15.00 per share, for net proceeds of $113.4 million after deducting underwriting discounts and commissions and offering costs.
In January 2020, the Company received $50.3 million of net proceeds, after deducting the underwriting discounts and commissions, from its public offering of 4,300,000 shares of the Company's common stock at a public offering price of $21.50 per share, of which 2,490,053 shares were offered and sold by the Company. Further, in February 2020, the underwriters fully exercised their option to purchase 645,000 shares of the Company's common stock at a public offering price of $21.50 per share for an additional net proceeds of $13.0 million to the Company, after deducting underwriting discounts and commissions. The total public offering costs incurred in connection with the follow-on offering were allocated based on the gross proceeds received by the Company and the other selling shareholders on a pro-rated basis. Public offering cost of $0.4 million allocated to selling of shares by the Company was charged against the gross proceeds received from the follow-on offering. Public offering costs of $0.2 million allocated to selling of shares by the selling shareholders was recognized as transaction costs within general and administrative expenses on the unaudited condensed consolidated statements of operations in the three months ended March 31, 2020.
2. Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information required by GAAP for complete financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments that are necessary for a fair statement of the Company’s consolidated financial information. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other interim period or for any other future year.
The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto for the year ended December 31, 2019 contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 11, 2020.
Risks and Uncertainties
In late 2019, SARS-CoV-2, a novel strain of coronavirus which causes the disease COVID-19, was reported in China, and in March 2020 the World Health Organization declared it a pandemic. The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the response to the pandemic is in its early stages and information is rapidly evolving. The Company's customers which include hospitals and medical centers are diverting resources to treat COVID-19 patients and deferring elective surgical procedures, both of which are likely to impact the Company's revenues as well as receivable collections and inventory obsolescence. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is likely that it could cause a local and/or global recession. Such economic disruption could have a material adverse effect on the Company's business. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.
8


SI-BONE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company's customers, all of which are uncertain and cannot be predicted. The Company's future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, excess and obsolete inventory, and the impact of any initiatives and programs that the Company may undertake to address financial and operations challenges faced by its customers.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant accounting estimates and management judgments reflected in the consolidated financial statements include: fair value of assets and liabilities; analysis of the allowance for doubtful accounts; inventory valuation; valuation of deferred tax assets, including related valuation allowances; stock-based compensation; and useful lives of long lived assets. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.
Significant Accounting Policies
The Company’s significant accounting policies are disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. There have been no material changes to these accounting policies.
JOBS Act Accounting Election
As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies. Those standards apply to companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. The Company continues to be an emerging growth company until December 31, 2023, unless one of the following occurs: (i) if the Company's total annual gross revenues are $1.07 billion or more; or (ii) the Company has issued more than $1.0 billion in non-convertible debt in the past three years; or (iii) the Company becomes a "large accelerated filer," as defined in Rule 12b-2 of the Exchange Act.

Segments
The Company manages and operates as one reportable segment. The Company derives substantially all of its revenue from sales to customers in the U.S. Revenue by geography is based on billing address of the customer. No single country outside the U.S. accounts for more than 10% of the total revenue during the periods presented. Long-lived assets held outside the U.S. are immaterial. The table below summarizes the Company's revenue by geography:
Three Months Ended March 31,
20202019
(in thousands)
United States$15,297  $13,450  
International1,524  1,541  
$16,821  $14,991  
9


SI-BONE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

Adoption of New Revenue Recognition Standard

The Company adopted the new revenue recognition standards ("ASC 606") using the modified retrospective method effective for the year ended December 31, 2019. This approach was applied to all contracts that were not completed as of January 1, 2019. As an emerging growth company that elected to take advantage of the JOBS Act accounting election, the Company was not required to adopt the new revenue standard in the interim reporting periods on the year of adoption and is not required, and intends not, to revise its 2019 interim periods which were reported under previous revenue recognition standards ("ASC 605"). The adoption of ASC 606 did not result in a material impact on the Company’s condensed consolidated financial statements and no adjustment was made to the opening balance of accumulated deficit at January 1, 2019. ASC 606's core principle is that a reporting entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at hospital or medical facilities, which represents majority of the Company's revenue, the Company continues to recognize the revenue upon completion of the procedure and authorization by the customer, net of rebates and price discounts. As it relates to sale of products through distributors and hospitals where product is ordered in advance of the procedure, the Company continues to recognize the revenue upon shipments to the customers, net of rebates and price discounts. Additionally, ASC 606 requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. The Company’s sales commissions paid to its sales representatives is generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. As such, the Company recognize sales commission as expense when incurred.

The Company disaggregates revenues from contracts with customers into geographical regions. The Company determined that disaggregating revenue into these categories depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by regional economic factors. For information regarding revenue by geography, refer to Segments in “Note 2 - Summary of Significant Accounting Policies" in the accompanying Notes to Condensed Consolidated Financial Statements.

Recently Issued Accounting Standards Not Yet Effective
        In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842), which requires that lessee's recognize a right-of-use asset and a lease liability for all leases with lease terms greater than twelve months in the balance sheet. A lease liability is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset is an asset that represents the lessee’s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date.  In July 2018, the FASB issued ASU 2018-10 and ASU 2018-11, which provides clarification on the narrow aspects of the guidance and provide an additional transition method to adopt the new leases standard. The new transition method allows an entity to recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In March 2019, the FASB issued ASU 2019-01, which provides clarification on implementation issues associated with adopting ASU 2016-02. The new leases standard must be adopted using a modified retrospective transition method and allows for the application of the new guidance at the beginning of the earliest comparative period presented or at the adoption date. In November 2019, the FASB issued ASU 2019-10, which revised the mandatory effective dates of the new lease standard. For public companies, the new guidance remained effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the new guidance is now effective for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. Early adoption is still permitted for any interim or annual financial statements not yet issued.

10


SI-BONE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

As an emerging growth company, the new lease standard is now effective for the Company for the fiscal year ending December 31, 2021 and interim periods within fiscal year ending December 31, 2022. The Company is currently evaluating the impact of this standard on its consolidated financial statements including the timing of its adoption. The Company anticipates to elect several practical expedients that permit the Company not to reassess (1) whether a contract is or contains a lease, (2) the classification of existing leases, and (3) whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. The Company expects that the adoption of this new standard will have a material impact on its balance sheet. The most significant impact would be the recognition of operating lease right-of-use assets and liability. The standard is not expected to have a material impact to the Company's consolidated statements of income and cash flows.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. FASB issued ASU 2019-05 in May 2019 and ASU 2019-08 in November 2019 for codification improvements of Topic 326. The new standard revises the accounting requirements related to the measurement of credit losses and will require organizations to measure all expected credit losses for financial assets based on historical experience, current conditions and reasonable and supportable forecasts about collectability. Assets must be presented in the financial statements at the net amount expected to be collected. In November 2019, the FASB issued ASU 2019-10, which defers the effective date of ASU 2016-13 for public companies that are eligible to be smaller reporting companies and all other companies, to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. In February 2020, the FASB issued ASU 2020-02, which provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses. The Company is currently evaluating the impact of this standard on its consolidated financial statements, but do not expect the standard will have a material impact on the Company's consolidated financial statements.
In June 2018, the FASB issued ASU 2018-07, Improvements to Non-employee Share-Based Payment Accounting. ASU 2018-07 expands the scope of Topic 718, Compensation-Stock Compensation, to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. ASU 2018-07 supersedes Subtopic 505-50, Equity-Based Payments to Non-Employees. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption date of ASC 606. The Company is currently assessing the impact of this new guidance but does not expect it to have a material impact on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurements, which eliminates, adds or modifies certain disclosure requirements for fair value measurements. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This update is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted to adopt either the entire standard or only the provisions that eliminate or modify the requirements. The Company is currently assessing the impact of this new guidance but does not expect it to have a material impact on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.

11


SI-BONE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

3. Marketable Securities

All of the Company's marketable securities were available-for-sale and were classified based on their maturities. Marketable securities with remaining maturities at the date of purchase of three months or less are classified as cash equivalents. Short term investments are securities that original maturity or remaining maturity is greater than three months and not more than twelve months. Long-term investments are securities for which the original maturity or remaining maturity is greater than twelve months.

The table below summarizes the marketable securities:
March 31, 2020
Amortized CostUnrealized GainsUnrealized LossesAggregate Fair Value
(in thousands)
Money market funds$62,194  $—  $—  $62,194  
Cash equivalents62,194  —  —  62,194  
U.S. treasury securities52,025  323    52,348  
Corporate bonds11,816  4  (47) 11,773  
Commercial paper13,252      13,252  
Short-term investments77,093  327  (47) 77,373  
Corporate bonds1,278    (4) 1,274  
Long-term investments1,278    (4) 1,274  
Total marketable securities$140,565  $327  $(51) $140,841  

December 31, 2019
Amortized CostUnrealized GainsUnrealized LossesAggregate Fair Value
(in thousands)
Money market funds$3,068  $—  $—  $3,068  
Commercial paper2,495  —  —  2,495  
Cash equivalents5,563  —  —  5,563  
U.S. treasury securities67,051  34  (2) 67,083  
Corporate bonds9,075  24  (2) 9,097  
Commercial paper5,165      5,165  
Short-term investments81,291  58  (4) 81,345  
Corporate bonds1,278      1,278  
Long-term investments1,278      1,278  
Total marketable securities$88,132  $58  $(4) $88,186  
The long-term investments outstanding as of March 31, 2020 and December 31, 2019 mature in April 2021.
Unrealized gains and losses on available-for-sale securities are recorded in accumulated other comprehensive income (loss) on the condensed consolidated balance sheets. The Company evaluates its investments to assess whether those in unrealized loss positions are other-than-temporarily impaired. The Company considers impairments to be other-than-temporary if it is related to deterioration in credit risk or if it is likely the Company will sell the securities before the recovery of their cost basis. The Company did not identify any of its marketable securities as other-than-temporarily impaired as of March 31, 2020 and December 31, 2019.
12


SI-BONE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

4. Fair Value Measurement
Carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The carrying value of the Company’s long-term debt also approximates fair value based on management’s estimation that a current interest rate would not differ materially from the stated rate. There were no other financial assets or liabilities that required fair value hierarchy measurements and disclosures for the periods presented.
The table below summarizes the fair value of the Company’s marketable securities measured at fair value on a recurring basis based on the three-tier fair value hierarchy:
March 31, 2020
Level 1Level 2Level 3Total
(in thousands)
Marketable securities
Money market funds
$62,194  $  $  $62,194  
U.S. treasury securities52,348      52,348  
Corporate bonds  13,047    13,047  
Commercial paper  13,252    13,252  
Total marketable securities$114,542  $26,299  $  $140,841  
December 31, 2019
Level 1Level 2Level 3Total
(in thousands)
Marketable securities
Money market funds
$3,068  $  $  $3,068  
U.S. treasury securities67,083      67,083  
Corporate bonds  10,375    10,375  
Commercial paper  7,660    7,660  
Total marketable securities$70,151  $18,035  $  $88,186  

13


SI-BONE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)


5. Balance Sheet Components
Inventory
As of March 31, 2020 and December 31, 2019, inventory consisted entirely of finished goods.
Property and Equipment, net:
March 31, 2020December 31, 2019
 (in thousands)
Machinery and equipment
$4,999  $4,613  
Construction in progress
1,994  1,854  
Computer and office equipment
605  598  
Leasehold improvements
502  497  
Furniture and fixtures
189  187  
8,289  7,749  
Less: Accumulated depreciation and amortization
(4,020) (3,795) 
$4,269  $3,954  
Depreciation expense was $0.2 million and $0.2 million for the three months ended March 31, 2020 and 2019, respectively.
Accrued Liabilities and Other:
March 31, 2020December 31, 2019
 (in thousands)
Accrued compensation and related expenses
$4,717  $7,274  
Accrued litigation expense
3,200  3,200  
Accrued professional services
571  392  
Others
796  739  
$9,284  $11,605  

6. Commitments and Contingencies
Operating Leases
The Company has a non-cancelable operating lease for an office building space, located in Santa Clara, California which expires in May 2025. The Company also has non-cancelable operating leases for its office building spaces in Gallarate, Italy and Mannheim, Germany which both expire in November 2024, and in Knaresborough, United Kingdom, which expires in December 2026. Further, the Company also leases vehicles under operating lease arrangements for certain of its sales personnel in Europe which expire various times in 2020 to 2023.
Rent expense is recorded over the lease terms on a straight-line basis. Rent expense charged to operations under operating leases was $0.3 million and $0.3 million for three months ended March 31, 2020 and 2019, respectively.

14


SI-BONE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

The table below summarizes aggregate future minimum lease payments under all leases as of March 31, 2020:
Year ending December 31,(in thousands)
2020 (remaining nine months)$850  
20211,024  
2022952  
2023866  
2024867  
Thereafter363  
$4,922  
Purchase Commitments and Obligations
The Company has certain purchase commitments related to its inventory management with certain manufacturing suppliers wherein the Company is required to purchase the amounts forecasted in a blanket purchase order. The contractual obligations represent future cash commitments and liabilities under agreements with third parties and exclude orders for goods and services entered into in the normal course of business that are not enforceable or legally binding. These outstanding commitments amounted to $0.2 million and $0.4 million as of March 31, 2020 and December 31, 2019, respectively.

Legal Proceedings

On February 6, 2019, a putative class action captioned Eric B. Fromer Chiropractic, Inc. ("Plaintiff") v. SI-BONE, Inc. (Civil Action No. 5:19-cv-633-SVK), was filed in the U.S. District Court, Northern District of California. The complaint alleges violations of the Telephone Consumer Protection Act (the “TCPA”) on behalf of an individual and a putative class of persons alleged to be similarly situated. The complaint alleges that the Company sent invitations to an educational dinner event to health care providers by way of facsimile transmission. The TCPA prohibits using a fax machine to send unsolicited advertisements not including proper opt-out instructions or to send unsolicited advertisements to persons with whom the sender did not have an established business relationship. The plaintiff sought various forms of relief, including statutory damages of $500 for each violation of the TCPA or, in the alternative, treble damages of up to $1,500 for each knowing and willful violation of the TCPA and a permanent injunction prohibiting the Company from sending or having sent advertisements by way of facsimile transmission. On December 23, 2019 the parties filed a joint stipulation of dismissal of the case in the District Court in the Northern District of California and on January 14, 2020, the parties executed a definitive settlement agreement (the "Settlement Agreement") pursuant to which, the Company agreed to settle all disputes regarding the advertising faxes to the settlement class.

As this lawsuit is being resolved through a negotiated settlement and class resolution process, the Company believes that it will incur a loss associated with resolution of the claims against it. The Company has accrued litigation expense of $3.2 million during the year ended December 31, 2019 within general and administrative expenses in the consolidated financial statements. The accrual reflects the estimable and probable costs that the Company may incur based on estimated claims submitted by members of the settlement class, as defined in the Settlement Agreement. As of March 31, 2020, the total accrued litigation expense remained the same as of December 31, 2019. The final disposition of the lawsuit may result in a loss in excess of the aggregate recorded amount.

Indemnification
The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made.
The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.
The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. No liability associated with such indemnifications has been recorded to date.
15


SI-BONE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

7. Borrowings
The following table summarizes the outstanding borrowings from the term loan described below, as of the dates presented:
March 31, 2020December 31, 2019
 (in thousands)
Principal outstanding$40,000  $40,000  
Less: Unamortized debt issuance costs(712) (777) 
Outstanding debt, net of debt issuance costs$39,288  $39,223  
Classified as:
Current portion of long-term borrowings$8,731  $4,358  
Long-term borrowings$30,557  $34,865  

The outstanding debt is related to a term loan entered by the Company with Biopharma Credit Investments IV Sub LP, or Pharmakon, in October 2017 for total loan proceeds of $40.0 million. The term loan includes an interest-only period for 35 months through September 2020 and is then repaid in equal quarterly principal payments plus interest through December 2022 and carries a fixed interest rate of 11.5%. The term loan includes a pre-payment fee equal to the remaining interest due for the first 30 months of the agreement if it is prepaid within the first 30 months, a 2% prepayment penalty for months 31-48, and a 1% penalty for months 49-60. The loan is a senior obligation secured with a blanket first lien on the assets of the Company. The effective interest rate for the three months ended March 31, 2020 and 2019 was 12.3% and 12.2%, respectively.
The table below summarizes annual future minimum principal payments under the loan agreement as of March 31, 2020:
Year ending December 31,(in thousands)
2020 (remaining nine months)$4,444  
202117,778  
202217,778  
Total future minimum payments
40,000  
Less: Amount representing debt issuance costs
(712) 
Long-term borrowings
$39,288  
The term loan requires the Company to maintain a minimum cash balance of $5.0 million and to meet either minimum net sales or trailing 12-month consolidated earnings before interest, taxes, depreciation, and amortization targets. The Company was in compliance with all debt covenants as of March 31, 2020. Due to uncertainties surrounding the impact of the COVID-19 pandemic, there is a substantial risk that the Company may not meet the remaining minimum net sales or the trailing 12-month consolidated EBITDA targets in future quarters. If the Company is not in compliance with these requirements, the loan may become due immediately at Pharmakon's option.
8. Stock-Based Incentive Compensation Plans
Stock Options

The table below summarizes the stock option activity for the three months ended March 31, 2020:
Number of
Shares
Weighted-
Average
Exercise
Price
Outstanding as of December 31, 20192,718,971  $8.02
Granted
26,236  17.31
Exercised
(43,334) 4.03
Canceled and forfeited(1,319) 12.87
Outstanding as of March 31, 20202,700,554  8.17
16


SI-BONE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

As of March 31, 2020, there was $5.0 million of unrecognized compensation cost related to stock options granted. These costs are expected to be recognized over a period of approximately 2.4 years.

The table below summarizes the weighted average grant date fair value per share and the assumptions used to estimate the grant date fair value of the stock options granted during the respective periods using the Black-Scholes option-pricing model:
Three Months Ended March 31,
20202019
Weighted average grant date fair value per share
$8.37$10.40
Expected term (years)
5.5to7.05.0to7.0
Expected volatility
46.74%to47.20%42.00%to47.00%
Risk-free interest rate
1.56%to1.64%2.52%to2.59%
Dividend yield
%%

Early Exercise of Unvested Stock Options
Early exercises of stock options are subject to a right of repurchase by the Company of any unvested shares. The repurchase rights lapse over the original vesting period of the options. The Company accounts for the cash received in consideration for the early exercised options as a liability included in accrued liabilities, which is then reclassified to stockholders’ equity as the options vest. As of March 31, 2020 and December 31, 2019, the Company had a total of 15,567 and 21,404 shares of common stock, respectively, subject to repurchase under the 2008 Stock Option Plan and $0.1 million and $0.1 million, respectively, of associated liabilities for the repurchase.
Restricted Stock Units
The table below summarizes restricted stock units activity for the three months ended March 31, 2020:
Number of SharesWeighted Average Grant Date Fair Value
Outstanding as of December 31, 2019543,041$19.72
Granted868,68320.43
Vested(63,938) 21.00
Canceled and forfeited(5,575)18.43
Outstanding as of March 31, 2020